A Phase 2 multicenter study of the use of autologous tumor-infiltrating lymphocytes (LN-145) in patients with metastatic non-small-cell lung cancer.
Contact Information for Access
Status
ATTIVO
Objective of the study
The objectives of the study are to evaluate the efficacy of TIL infusion and to prolong survival.
ClinicalTrials.gov ID NCT04614103
Sponsor: Iovance Biotherapeutics, Inc.
Medication
TIL, LN-145 (tumor-infiltrating lymphocytes)
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with previously treated advanced and/or metastatic non-small cell lung cancer (NSCLC) who do not have targetable mutations (EGFR-, ALK-, and ROS1-negative).
Back to search page